Ariad, Investors Strike $3.5M Deal Over Cancer Drug Outlook
Takeda Pharmaceutical Co. Ltd. unit Ariad Pharmaceuticals Inc. has agreed to pay a proposed class of investors $3.5 million to settle claims it lied about the labeling prospects of its leukemia...To view the full article, register now.
Already a subscriber? Click here to view full article